Načítá se...
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
BACKGROUND: Nintedanib reduces the rate of decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib...
Uloženo v:
| Vydáno v: | BMC Pulm Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8293560/ https://ncbi.nlm.nih.gov/pubmed/34289823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-021-01598-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|